Andelyn Biosciences Launches Lentiviral Vector Manufacturing Platform

Andelyn Biosciences has launched a standardized lentiviral vector manufacturing platform, expanding its contract development and manufacturing offerings as cell and gene therapy companies look for more reliable ways to move programs from laboratory research into clinical-grade production.

The new platform, called LVV Curator, is designed to address one of the sector’s persistent manufacturing bottlenecks: the transition from research-grade processes to current good manufacturing practice, or GMP, production. The platform uses a predefined manufacturing framework intended to reduce development time, improve consistency and support eventual scale-up.

“Developers should not have to choose between speed and quality when advancing lentiviral programs,” said Wade Macedone, CEO at Andelyn Biosciences. “With LVV Curator, we are bringing the same platform discipline under the same quality systems that power our commercial AAV manufacturing to LVV, enabling sponsors to advance their therapies with greater confidence from the start.”

Andelyn is positioning the launch as an extension of its broader Curator platform approach, which the company says has supported more than 100 adeno-associated virus, or AAV, programs. By adapting that operating model to lentiviral vector manufacturing, the company is betting that established process controls and commercial-style quality systems can become a differentiator in a market where manufacturing execution remains a key constraint.

The platform also includes an early-development collaboration model built around design-of-experiments methods and process optimization, as well as use of a HEK293 cell line with prior clinical and regulatory experience. Those features are meant to help sponsors establish manufacturing processes earlier while potentially reducing technical and regulatory friction later in development.

LVV Curator is aimed at early-phase programs, where developers often face pressure to generate clinical material quickly without sacrificing reproducibility or future scalability. For the broader pharma services market, the launch underscores how CDMOs are increasingly packaging manufacturing know-how into platform offerings that promise shorter timelines, lower risk and clearer paths to regulatory readiness.